The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.76
Bid: 5.00
Ask: 5.76
Change: 0.00 (0.00%)
Spread: 0.76 (15.20%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 5.76
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: SulNOx raises funds; Synairgen shares trial results

Fri, 23rd Dec 2022 17:05

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

SulNOx Group PLC - London-based green technology company - Raises around GBP760,000 via placing and subscription of new shares at 11.5 pence price. Says largest shareholder Nistad AS invests further GBP80,000 to hold 13% in equity at SulNox. Follows announcement from yesterday which proposed fundraise to raise a minimum of GBP750,0000. "Despite difficult market conditions, we are pleased to have received institutional investor backing for SulNOx as an ESG, energy transition company with tremendous potential from reducing fossil fuel consumption and emissions across the globe," says Chief Executive Officer Ben Richardson. "Following the fundraising, SulNOx will have a runway to deliver increasing revenues and be able to accelerate our growth plans through 2023."

----------

Cindrigo Holdings Ltd - London-based clean energy producer - Reaches agreement with Danir AB, its largest shareholder and creditor, to provide new funding and restructure short-term debt of GBP4.3 million into long-term convertible loans. Danir provides additional loan funding of GBP750,000, following BK Fortuna AS's reported failure to provide agreed funding to Cindrigo, as announced on September 30. Says additional Danir funding is via 24-month convertible loan with a 5% interest rate per year. Says this loan is convertible into Cindrigo shares from 60 days after the company is readmitted to listing, with conversion price equal to the higher of either a 25% discount to the 30-day volume-weighted average share price or the minimum price per share of 125 pence. Existing GBP3.8m debt funding from Danir will be restructured and replaced by issue of new 10-year zero coupon convertible loan notes with a conversion price of 15p per share. Can be converted for a maximum of 25.3 million new Cindrigo shares.

----------

Synairgen PLC - Southampton, England-based respiratory company developing SNG001 treatment, containing the broad-spectrum antiviral protein interferon beta - Publishes results of Sprinter phase 3 trial in the European Respiratory Journal Open Research. Says while Sprinter trial does not meet the primary endpoints of discharge from the hospital and recovery, there is an encouraging signal in reduction in the relative risk of progression to severe disease or death with 35 days. Says SNG001 is well tolerated, as shown in previous clinical trials. Chief Scientific Officer & Lead Author Phillip Monk says: "The results from the SG016 phase 2 and the Sprinter trial of SNG001 in hospitalised patients, and the Activ-2 trial in the home setting, suggest that SNG001 may be preventing progression to severe disease. With these data, we remain confident in the potential of SNG001 as a broad-spectrum antiviral for high-risk patient populations infected with respiratory viruses including influenza and RSV and are focused on its continued clinical development." Says SNG001 is not approved for use anywhere in the world.

----------

Wentworth Resources PLC - Tanzania-focused natural gas production company - Says it expects to achieve an average gross daily production rate of around 90 million standard cubic feet per day for 2022, compared to previous guidance of between 75MMscf/d and 85MMscf/d. As of Monday, current production levels are steady at a supply-constrained 90MMscf/d, below current demand nominations of 95MMscf/d from its key offtaker the Tanzania Petroleum Development Corp. Says Mnazi Bay joint venture is undertaking an infield workover and perforation programme, aiming to meet gas demand nominations in 2023. Hopes production levels will reach 90MMscf/d from late 2024 until at least 2027. Cash is USD30.0 million on December 1, while joint venture capital expenditure budget for 2023 is USD13.5 million.

----------

SEEEN PLC - London-based media and technology platform - Raises around GBP2.6 million via open offer of 523,887 shares. Says net proceeds are intended to bolster company's sales and marketing team, alongside investing into technology development projects to support planned next stage of growth.

----------

Dolphin Capital Investors Ltd - Cardiff, Wales-based investor in high-end resort developments in the eastern Mediterranean - Completes the EUR17.9 million disposal of its entire interest in the One&Only at Kea Island project. Prior to sale, Dolphin was 67% owner of Single Purpose Vehicle Ten Ltd, which owned 50% of OOKI, giving Dolphin Capital an effective 33% equity interest in OOKI. Receives EUR900,000 of sale proceeds on December 5 as an advance payment. Receives the remaining EUR17.0 million balance on completion. Around EUR13.0 million of the disposal proceeds used to repay its existing loan facility by December 31, which Dolphin Capital drew down in June and July. Says all debt has now been fully repaid.

----------

Curtis Banks Group PLC - Bristol-based financial services company - Says Nucleus Financial Platforms Ltd completes its due diligence amid advanced discussions over a possible offer for the entire share capital of Curtis Banks. Says both parties are close to agreeing transaction. Extends deadline for nucleus to announce offer to January 9 from Friday. Follows announcement of a potential takeover on November 25.

----------

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
18 Apr 2019 11:52

Synairgen Non-Executive Director Paul Clegg To Retire In June

LONDON (Alliance News) - Synairgen PLC on Thursday said Non-Executive Director Paul Clegg will retire from the company's board after the company's annual general meeting on June Buchanan,

Read more
14 Mar 2019 14:47

Synairgen broadens SNG001 trial after committee review

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Thursday that its data safety monitoring committee had completed its planned safety review of the second part of the phase 2 clinical trial of its inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD).

Read more
14 Mar 2019 11:37

Synairgen Gets Positive Safety Review Of SNG001 Candidate

LONDON (Alliance News) - Synairgen PLC on Thursday said the Data Safety Monitoring Committee has completed its planned safety review of a clinical trial of therapeutic candidate, SNG001.The

Read more
25 Feb 2019 11:41

Synairgen Swings To Annual Loss As Costs Rise And Revenue Drops

LONDON (Alliance News) - Synairgen PLC on Monday said it swung to an annual loss due to higher research costs and the lack of a non-recurring GBP5 million payment from Pharmaxis received in 2018,

Read more
22 Oct 2018 11:53

Synairgen Begins Dosing For Next Stage Of SNG001 Clinical Trial

LONDON (Alliance News) - Synairgen PLC said Monday it has begun dosing for the next part of its SNG001 chronic obstructive pulmonary disease treatment trial.The respiratory drug discovery a

Read more
22 Oct 2018 09:20

Synairgen begins second part of SNG001 Phase II trial

(Sharecast News) - Respiratory drug discovery and development company Synairgen has started the second part of its Phase II clinical trial for its wholly-owned inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD), it announced on Monday.

Read more
25 Sep 2018 13:48

Synairgen Fundraises To Progress Clinical Tests As Interim Loss Widens (ALLISS)

LONDON (Alliance News) - Synairgen PLC on Tuesday announced fundraising to cover the clinical trials of its wholly-owned antiviral therapy SNG001 after its loss widened in the first half of drug a

Read more
15 Mar 2018 12:57

Synairgen Swings To Profit On Lump Sum Payment As Pipeline Progresses

LONDON (Alliance News) - Respiratory drug development firm Synairgen PLC swung to a full year profit Thursday after a lump sum payment from a collaboration partner offset and

Read more
12 Oct 2016 09:52

Synairgen shares drop as AstraZeneca stops asthma drug study

(ShareCast News) - Synairgen's, the respiratory drug discovery and development company, hit the skids after its partner Astrazeneca announced that it has dropped its clinical trial for asthma drug AZD9412. AZD9412, which is a form of inhaled interferon beta, was investigated in an INEXAS trial in pa

Read more
22 Mar 2016 11:07

Synairgen Swings To Loss But Gets Good LOXL2 Trial Results

Read more
21 Mar 2016 16:06

Earnings, Trading Statements Calendar - Week Ahead

Read more
12 Nov 2015 11:35

DIRECTOR DEALINGS: Synairgen Directors Snap Up 163,000 Shares

Read more
16 Sep 2015 13:03

Synairgen's profit dips, R and D expenditure reduced

(ShareCast News) - Synairgen has posted an after tax loss of £0.91m for the six months to 30 June, down from a profit of £1.90m in the same period last year. The respiratory drug discovery and development company announced its unaudited interim results for the six months ended 30 June 2015. Researc

Read more
16 Sep 2015 09:50

Synairgen Swings To Loss As AstraZeneca Revenue Bump Doesn't Repeat

Read more
5 Aug 2015 10:21

Synairgen shares surge on research collaboration deal

(ShareCast News) - Synairgen surged after announcing that it has entered into a research collaboration deal with Australian pharmaceutical company Pharmaxis. The respiratory drug discovery and development company said they will develop a selective inhibitor to the lysyl oxidase type 2 enzyme to trea

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.